Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Buprenorphine may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for This medicine has been prescribed for you to relieve moderate, long-lasting pain that requires the use of a strong painkiller. It contains buprenorphine which belongs to a class of medicines called opioids, which are 'pain relievers'. This medicine has been prescribed to you and should not be given to anyone else. Opioids can cause addiction and you may get withdrawal symptoms if you stop taking it suddenly. Your prescriber should have explained how long you will be taking it for and when it is appropriate to stop, how to do this safely. BuTrans patches should not be used to relieve acute pain.
BuTrans patches act through the skin. After application, buprenorphine passes through the skin into the blood. Each patch lasts for seven days.
e BuTrans patches Do not use BuTrans patches:
If you notice any of these signs, speak to your doctor to discuss the best treatment pathway for you, including when it is appropriate to stop and how to stop safely (see section 3, If you stop taking BuTrans). The use of these medicines together with BuTrans patches can lead to serotonin syndrome, a potentially life-threatening condition if (see "Other medicines and BuTrans patches"); • You suffer from seizures, fits or convulsions; • You suffer from a breathing related sleep disorder (sleep apnoea); • You have a severe headache or feel sick due to a head injury or increased pressure in your skull (for instance due to brain disease). This is because the patches may make symptoms worse or hide the extent of a head injury; • You are feeling light-headed or faint; • You have severe liver problems; • You have a high temperature, as this may lead to larger quantities of the active ingredient being absorbed into the blood than normal; • You suffer from constipation. Using this medicine regularly, particularly for a long time, can lead to addiction. Your prescriber should have explained how long you will be using it for and when it is appropriate to stop, how to do this safely. Rarely, increasing the dose of this medicine can make you more sensitive to pain. If this happens, you need to speak to your prescriber about your treatment. Addiction can cause withdrawal symptoms when you stop using this medicine. Withdrawal symptoms can include restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, loss of appetite, shaking, shivering or sweating. Your prescriber will discuss with you how to gradually reduce your dose before stopping the medicine. It is important that you do not stop taking the medicine suddenly as you will be more likely to experience withdrawal symptoms. Opioids should only be used by those they are prescribed for. Do not give your medicine to anyone else. Taking higher doses or more frequent doses of opioid, may increase the risk of addiction. Overuse and misuse can lead to overdose and/or death. Sleep-related breathing disorders BuTrans patches can cause sleep-related breathing disorders such as sleep apnoea (breathing pauses during sleep) and sleep related hypoxemia (low oxygen level in the blood). The symptoms can include breathing pauses during sleep, night awakening due to shortness of breath, difficulties to maintain sleep or excessive drowsiness during the day. If you or another person observe these symptoms, contact your doctor. A dose reduction may be considered by your doctor. This medicine may cause application site reactions which are usually presented by a mild or moderate skin inflammation, and their typical appearance may include redness, swelling, itching, rash, small blisters, and painful/burning sensation at the application site. Most commonly the cause is skin irritation, and these reactions stop after BuTrans patches are removed. More serious allergic reactions may occur such as blisters with discharge, which may spread outside the application site and may not resolve rapidly after BuTrans removal. Chronic allergic reactions may lead to open wounds, bleeding, ulcers, skin discoloration and infections. If you notice any of the above skin reactions, please contact your doctor.
This medicine may increase your sensitivity to pain particularly at high doses. Tell your doctor if this happens. A reduction in your dose or a change in your medicine may be necessary. Do not use if you have pain which lasts only for a short period or pain after having an operation because of the increased risk of dependence and developing serious breathing problems. If you are going to have an operation, or have just had an operation, please tell the doctor at the hospital if you are currently treated with BuTrans transdermal patch to discuss your pain management. Similar to other opioids, BuTrans patches may affect the normal production of hormones in the body, such as cortisol or sex hormones, particularly if you have taken high doses for long period of time. Children and adolescents Do not give this medicine to children below 18 years. Other medicines and BuTrans patches Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Some medicines may increase the side effects of BuTrans patches and may sometimes cause very serious reactions. Do not take any other medicines whilst taking BuTrans patches without first talking to your doctor, especially:
• • • • •
prescribe BuTrans patches together with sedative medicines the dose and duration of concomitant treatment should be limited by your doctor. Please tell your doctor about all sedative medicines you are taking, and follow your doctor's dose recommendation closely. It could be helpful to inform friends or relatives to be aware of the signs and symptoms stated above. Contact your doctor when experiencing such symptoms. Gabapentin or pregabalin to treat epilepsy or pain due to nerve problems (neuropathic pain). Medicines to treat depression. Medicines used to treat allergies, travel sickness or nausea (antihistamines or antiemetics). Muscle relaxants. Medicines to treat Parkinson's disease
Using BuTrans patches with food, drink and alcohol Alcohol may make some of the side effects worse and you may feel unwell if you drink alcohol whilst wearing BuTrans patches. Drinking alcohol whilst using BuTrans patches may also affect your reaction time. Pregnancy, breast-feeding and fertility Do not use BuTrans patches if you are pregnant or think you may be pregnant unless you have discussed this with your prescriber and the benefits of treatment are considered to outweigh the potential harm to the baby. If you use BuTrans patches during pregnancy, your baby may become dependent and experience withdrawal symptoms after the birth which may need to be treated. Do not use BuTrans patches while you are breastfeeding as buprenorphine passes into breast milk and will affect your baby. Ask your doctor or pharmacist for advice before taking this medicine. Driving and using machines BuTrans patches may affect your reactions to such an extent that you may not react adequately or quickly enough in the event of unexpected or sudden occurrences. This applies particularly:
Talk to your doctor or pharmacist if you are not sure whether it is safe for you to drive while taking this medicine.
BuTrans patches Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Before starting treatment and regularly during treatment, your doctor will discuss with you what you may expect from using BuTrans, when and how long you need to take it, when to contact your doctor, and when you need to stop it (see also, If you stop taking BuTrans). Different strengths of BuTrans patches are available. Your doctor will decide which strength of BuTrans patch will suit you best. When people first start using BuTrans, they often experience some nausea and vomiting (see section 4). This usually passes after the first week of treatment. It's a good idea to book a follow-up appointment with your doctor a week or two after you first start using BuTrans patches to ensure that you are taking the correct dose and to manage any side effects. During treatment, your doctor may change the patch you use to a smaller or larger one if necessary, or tell you to use a combination of up to two patches. Do not cut or divide the patch or use a higher dose than recommended. You should not apply more than two patches at the same time, up to a maximum total dose of 40 micrograms/hour. Your prescriber should have discussed with you how long the course of patches will last. They will arrange a plan for stopping treatment. This will outline how to gradually reduce the dose and stop taking the medicine. Adults and elderly patients Unless your doctor has told you differently, attach one BuTrans patch (as described in detail below) and change it every seventh day, preferably at the same time of day. Your doctor may wish to adjust the dose after 3-7 days until the correct level of pain control has been found. If your doctor has advised you to take other painkillers in addition to the patch, strictly follow the doctor's instructions, otherwise you will not fully benefit from treatment with the BuTrans patch. The patch should be worn for 3 full days before increasing the dose, this is when the maximum effect of a given dose is established. Patients under 18 years of age BuTrans patches should not be used in patients below the age of 18 years. Patients with kidney disease/dialysis patients In patients with kidney disease, no change in dose is necessary. Patients with liver disease In patients with liver disease, the effects and period of action of the BuTrans patch may be affected and your doctor will therefore check on you more closely. Before applying the BuTrans patch
•
Choose an area of non-irritated, intact skin on your upper arm, outer arm, upper chest, upper back or side of the chest. (See illustrations below). Ask for assistance if you cannot apply the patch yourself.
The BuTrans patch should be applied to a relatively hairless or nearly hairless skin site. If no suitable hair free sites are available the hairs should be cut off with a pair of scissors. Do not shave them off. Avoid skin which is red, irritated or has any other blemishes, for instance large scars. The area of skin you choose must be dry and clean. If necessary, wash it with cold or lukewarm water. Do not use soap, alcohol, oil, lotions or other detergents. After a hot bath or shower, wait until your skin is completely dry and cool. Do not apply lotion, cream or ointment to the chosen area. This might prevent your patch from sticking properly.
• •
Applying the patch Step 1: Each patch is sealed in a pouch. Just before use, cut the pouch along the dotted line with scissors. Be careful not to damage the transdermal patches with the scissors. Take out the patch. Do not use the patch if the pouch seal is broken. Step 2:
The sticky side of the patch is covered with a silvery protective foil. Carefully peel off half the foil. Try not to touch the sticky part of the patch.
Step 3: Stick the patch on to the area of skin you have chosen and remove the remaining foil. Step 4:
Press the patch against your skin with the palm of your hand and count slowly to 30. Make sure that the whole patch is in contact with your skin, especially at the edges.
Wearing the patch You should wear the patch for seven days. Provided that you have applied the patch correctly, there is little risk of it coming off. If the edges of the patch begin to peel off, they may be taped down with a suitable skin tape. You may shower, bathe or swim whilst wearing it. Do not expose the patch to extreme heat (e.g. heating pads, electric blanket, heat lamps, sauna, hot tubs, heated water beds, hot water bottle, etc) as this may lead to larger quantities of the active ingredient being absorbed into the blood than normal. External heat may also prevent the patch from sticking properly. If you have a high temperature this may alter the effects of BuTrans patches (see "Take special care" section above). In the unlikely event that your patch falls off before it needs changing, do not use the same patch again. Stick a new one on straight away (see "Changing the patch" below).
Changing the patch
Like all medicines, this medicine can cause side effects, although not everybody gets them. Serious side effects that may be associated with BuTrans patches are similar to those seen with other strong painkillers and include difficulty in breathing and low blood pressure. This medicine can cause allergic reactions, although serious allergic reactions are rare. Remove the patch and tell your doctor immediately if you get any sudden wheeziness, difficulties in breathing, swelling of the eyelids, face or lips, rash or itching especially those covering your whole body. Drug withdrawal When you stop using BuTrans patches you may experience drug withdrawal symptoms, which include restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, shaking, shivering or sweating. How do I know if I am addicted? If you notice any of the following signs whilst using BuTrans patches, it could be a sign that you have become addicted.
• • • • • • • • •
Cough, hiccups, wheezing. Wind. Weight loss. Dry skin. Spasms, aches and pains. Difficulty in beginning the flow of urine. Fever. An increase in accidental injuries (e.g. falls). Withdrawal symptoms such as agitation, anxiousness, sweating or shaking upon stopping using BuTrans patches (see section 'Drug withdrawal').
If you need to have blood tests remind your doctor that you are using BuTrans patches. This is important because BuTrans patches may change the way your liver works and this could affect the results of some blood tests. Rare (may affect up to 1 in 1000 people)
• •
Dermatitis contact (skin rash with inflammation which may include burning sensation), skin discolouration. Dependence and addiction (see section 'How do I know if I am addicted?').
Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
BuTrans patches Keep this medicine out of the sight and reach of children. Do not use BuTrans patches after the expiry date which is stated on the carton and on the pouch. The expiry date refers to the last day of that month. After the expiry date, take any unused patches to a pharmacy. Do not store BuTrans patches above 25°C. Do not use the patch if the pouch seal is broken. Store this medicine in a safe and secure place, where other people cannot access it. It can cause serious harm and be fatal to people who may take this medicine by accident, or intentionally when it has not been prescribed for them. Used patches must be folded over on themselves with the adhesive layer inwards, and discarded safely out of sight and reach of children. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What BuTrans patches contain The active ingredient is buprenorphine. BuTrans 5 microgram/hour transdermal patch Each transdermal patch contains 5 mg of buprenorphine in a patch size of 6.25 cm2 and releases about 5 micrograms of buprenorphine per hour (over a period of 7 days). BuTrans 10 microgram/hour transdermal patch Each transdermal patch contains 10 mg of buprenorphine in a patch size of 12.5 cm 2 and releases about 10 micrograms of buprenorphine per hour (over a period of 7 days). BuTrans 15 microgram/hour transdermal patch Each transdermal patch contains 15 mg of buprenorphine in a patch size of 18.75 cm 2 and releases about 15 micrograms of buprenorphine per hour (over a period of 7 days). BuTrans 20 microgram/hour transdermal patch Each transdermal patch contains 20 mg of buprenorphine in a patch size of 25 cm 2 and releases about 20 micrograms of buprenorphine per hour (over a period of 7 days). The other ingredients are:
BuTrans 5 microgram/hour transdermal patch comes as patch containing 5mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in BuTrans 5 microgram/hour transdermal patch is buprenorphine.
Medicines with the same active substance, strength and form include: Bunov 5 microgram/h transdermal patch, Butec 5 microgram/hour transdermal patch, Panitaz 5 micrograms/h Transdermal Patches. In total there are 5 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for BuTrans 5 microgram/hour transdermal patch, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Treatment of non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia.
BuTrans is not suitable for the treatment of acute pain.
BuTrans is indicated in adults.
Posology
BuTrans should be administered every 7th day.
Patients aged 18 years and over
The lowest BuTrans dose (BuTrans 5 microgram/hour transdermal patch) should be used as the initial dose. Consideration should be given to the previous opioid history of the patient (see section 4.5) as well as to the current general condition and medical status of the patient.
Prior to starting treatment with opioids, a discussion should be held with patients to put in place a strategy for ending treatment with buprenorphine in order to minimise the risk of addiction and drug withdrawal syndrome (see section 4.4).
Titration
During initiation of treatment with BuTrans, short-acting supplemental analgesics may be required (see section 4.5) as needed until analgesic efficacy with BuTrans is attained.
During the titration process, the dose may be adjusted every 3-days (72 hours). Thereafter, the 7-day dosing interval should be maintained. Subsequent dosage increases may then be titrated based on the need for supplemental pain relief and the patient's analgesic response to the patch.
To increase the dose, a larger patch should replace the patch that is currently being worn, or a combination of patches should be applied in different places to achieve the desired dose. It is recommended that no more than two patches are applied at the same time, up to a maximum total dose of 40 microgram/hour BuTrans. A new patch should not be applied to the same skin site for the subsequent 3-4 weeks (see section 5.2). Patients should be carefully and regularly monitored to assess the optimum dose and duration of treatment.
In the absence of adequate pain control, the possibility of hyperalgesia, tolerance and progression of underlying disease should be considered (see section 4.4). A BuTrans dose reduction or discontinuation of BuTrans treatment or treatment review may be indicated.
Conversion from opioids
BuTrans can be used as an alternative to treatment with other opioids. Such patients should be started on the lowest available dose (BuTrans 5 microgram/hour transdermal patch) and continue taking short-acting supplemental analgesics (see section 4.5) during titration, as required.
Paediatric population
The safety and efficacy of BuTrans in children below 18 years of age has not been established. No data are available.
Elderly
No dosage adjustment of BuTrans is required in elderly patients.
Renal impairment
No special dose adjustment of BuTrans is necessary in patients with renal impairment.
Hepatic impairment
There is no need for dosage adjustment of BuTrans in patients with mild to moderate hepatic impairment.
Buprenorphine is metabolised in the liver. The intensity and duration of its action may be affected in patients with impaired liver function. Therefore, such patients should be carefully monitored during treatment with BuTrans.
Patients with severe hepatic impairment may accumulate buprenorphine during BuTrans treatment. Consideration of alternate therapy should be considered, and BuTrans should be used with caution, if at all, in such patients.
Method of administration
Route of administration
Transdermal patch to be worn for 7 days. The patch must not be divided or cut into pieces.
Patch application
In order to ensure effective analgesia of buprenorphine and to minimise the potential of skin reactions (see section 4.4), the following directions of use should be followed:
BuTrans should be applied to non-irritated, intact skin of the upper outer arm, upper chest, upper back or the side of the chest, but not to any parts of the skin with large scars. BuTrans should be applied to a relatively hairless or nearly hairless skin site. If none are available, the hair at the site should be cut with scissors, not shaven.
If the application site must be cleaned, it should be done with clean water only. Soaps, alcohol, oils, lotions or abrasive devices must not be used. The skin must be dry before the patch is applied. BuTrans should be applied immediately after removal from the sealed sachet. Following removal of the protective layer, the transdermal patch should be pressed firmly in place with the palm of the hand for approximately 30 seconds, making sure the contact is complete, especially around the edges. If the edges of the patch begin to peel off, the edges may be taped down with suitable skin tape to ensure a 7 day period of wear. The patch should be worn continuously for 7 days. Bathing, showering, or swimming should not affect the patch. If a patch falls off, a new one should be applied and worn for 7 days.
Duration of administration
BuTrans should under no circumstances be administered for longer than absolutely necessary. If long-term pain treatment with BuTrans is necessary in view of the nature and severity of the illness, then careful and regular monitoring should be carried out (if necessary with breaks in treatment) to establish whether and to what extent further treatment is necessary.
Treatment goals and Discontinuation
Before initiating treatment with BuTrans, a treatment strategy including treatment duration and treatment goals, and a plan for end of the treatment, should be agreed together with the patient, in accordance with pain management guidelines. During treatment, there should be frequent contact between the physician and the patient to evaluate the need for continued treatment, consider discontinuation and to adjust dosages if needed. When a patient no longer requires therapy with BuTrans, it may be advisable to taper the dose gradually to prevent symptoms of withdrawal. In absence of adequate pain control, the possibility of hyperalgesia, tolerance and progression of underlying disease should be considered (see section 4.4).
After removal of the patch, buprenorphine serum concentrations decrease gradually and thus the analgesic effect is maintained for a certain amount of time. This should be considered when therapy with BuTrans is to be followed by other opioids. As a general rule, a subsequent opioid should not be administered within 24 hours after removal of the patch. At present, only limited information is available on the starting dose of other opioids administered after discontinuation of the transdermal patch (see section 4.5).
Patients with fever or exposed to external heat
While wearing the patch, patients should be advised to avoid exposing the application site to external heat sources, such as heating pads, electric blankets, hot water bottles, heat lamps, sauna, hot tubs, and heated water beds, etc, as an increase in absorption of buprenorphine may occur. When treating febrile patients, one should be aware that fever may also increase absorption resulting in increased plasma concentrations of buprenorphine and thereby increased risk of opioid reactions.
Duration of treatment
BuTrans should not be used longer than necessary.
BuTrans is contraindicated in:
BuTrans is contra-indicated in:
- patients with known hypersensitivity to the active substance buprenorphine or to any of the excipients (see section 6.1)
- opioid dependent patients and for narcotic withdrawal treatment
- conditions in which the respiratory centre and function are severely impaired or may become so
- patients who are receiving MAO inhibitors or have taken them within the last two weeks (see section 4.5)
- patients suffering from myasthenia gravis
- patients suffering from delirium tremens
BuTrans should be used with particular caution in patients with:
• Respiratory depression
• CNS depressants co-administration (see below and section 4.5)
• Serotonergic agents (see below and section 4.5)
• Psychological dependence [addiction], abuse profile and history of substance and/or alcohol abuse (see below)
• Sleep apnoea
• Acute alcohol intoxication
• Head injury, intracranial lesions or increased intracranial pressure, shock, a reduced level of consciousness of uncertain origin
• Severely impaired hepatic function (see section 4.2)
• Constipation
Respiratory depression
Significant respiratory depression has been associated with buprenorphine, particularly by the intravenous route. A number of overdose deaths have occurred when addicts have intravenously abused buprenorphine, usually with benzodiazepines concomitantly. Additional overdose deaths due to ethanol and benzodiazepines in combination with buprenorphine have been reported. (see Section 4.9). Caution should be exercised when prescribing BuTrans to patients known to have, or suspected of having, problems with drug or alcohol abuse or serious mental illness.
Concomitant use of opioids such as buprenorphine and sedative medicines such as benzodiazepines or related drugs may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing with these sedative medicines should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe buprenorphine concomitantly with sedative medicines, the lowest effective dose should be used, and the duration of treatment should be as short as possible.
The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms (see section 4.5).
Serotonin syndrome
Concomitant administration of BuTrans and other serotonergic agents, such as MAO inhibitors, selective serotonin re-uptake inhibitors (SSRIs), serotonin norepinephrine re-uptake inhibitors (SNRIs) or tricyclic antidepressants may result in serotonin syndrome, a potentially life-threatening condition (see section 4.5). If concomitant treatment with other serotonergic agents is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.
Symptoms of serotonin syndrome may include mental-status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms.
If serotonin syndrome is suspected, a dose reduction or discontinuation of therapy should be considered depending on the severity of the symptoms.
Buprenorphine is a µ-opioid agonist, acting as a full agonist with respect to analgesia and as a partial agonist with respect to its respiratory depressant properties (see section 5.1).
Tolerance and opioid use disorder (abuse and dependence)
Tolerance, physical and psychological dependence, and opioid use disorder (OUD) may develop upon repeated administration of opioids such as BuTrans . Repeated use of BuTrans can lead to OUD. A higher dose and longer duration of opioid treatment can increase the risk of developing OUD. Abuse or intentional misuse of BuTrans may result in overdose and/or death. The risk of developing OUD is increased in patients with a personal or a family history (parents or siblings) of substance use disorders (including alcohol use disorder), in current tobacco users or in patients with a personal history of other mental health disorders (e.g. major depression, anxiety and personality disorders).
Before initiating treatment with BuTrans and during the treatment, treatment goals and a discontinuation plan should be agreed with the patient (see section 4.2). Before and during treatment the patient should also be informed about the risks and signs of OUD. If these signs occur, patients should be advised to contact their physician.
Patients will require monitoring for signs of drug-seeking behavior (e.g. too early requests for refills). This includes the review of concomitant opioids and psycho-active drugs (like benzodiazepines). For patients with signs and symptoms of OUD, consultation with an addiction specialist should be considered.
Drug withdrawal syndrome
Prior to starting treatment with any opioids, a discussion should be held with patients to put in place a withdrawal strategy for ending treatment with buprenorphine.
Drug withdrawal syndrome may occur upon abrupt cessation of therapy or dose reduction. When a patient no longer requires therapy, it is advisable to taper the dose gradually to minimise symptoms of withdrawal. Tapering from a high dose may take weeks to months.
The opioid drug withdrawal syndrome is characterised by some or all of the following: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills, myalgia, mydriasis and palpitations. Other symptoms may also develop including irritability, agitation, anxiety, hyperkinesia, tremor, weakness, insomnia, anorexia, abdominal cramps, nausea, vomiting, diarrhoea, increased blood pressure, increased respiratory rate or heart rate.
If women take this drug during pregnancy, there is a risk that their newborn infants will experience neonatal withdrawal syndrome.
Hyperalgesia
Hyperalgesia may be diagnosed if the patient on long-term opioid therapy presents with increased pain. This might be qualitatively and anatomically distinct from pain related to disease progression or to breakthrough pain resulting from development of opioid tolerance. Pain associated with hyperalgesia tends to be more diffuse than the pre-existing pain and less defined in quality. Symptoms of hyperalgesia may resolve with a reduction of opioid dose.
Sleep-related breathing disorders
Opioids can cause sleep-related breathing disorders including central sleep apnoea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the total opioid dosage.
Skin reactions at application site
To minimise the risk of occurrence of application site skin reactions, it is important to follow the posology instructions (see section 4.2).
Application site reactions with BuTrans are usually presented by a mild or moderate skin inflammation (contact dermatitis), and their typical appearance may include erythema, oedema, pruritus, rash, small blisters (vesicles), and painful/burning sensation at the application site. Most commonly the cause is skin irritation (irritant contact dermatitis), and these reactions resolve spontaneously after BuTrans removal.
Patients and caregivers should be instructed accordingly to monitor the application sites for such reactions. If allergic contact dermatitis is suspected, relevant diagnostic procedures should be performed to determine if sensitisation has occurred and its actual cause (buprenorphine and/or other ingredients of the patch).
Since CYP3A4 inhibitors may increase concentrations of buprenorphine (see section 4.5), patients already treated with CYP3A4 inhibitors should have their dose of BuTrans carefully titrated since a reduced dosage might be sufficient in these patients.
BuTrans is not recommended for analgesia in the immediate post-operative period or in other situations characterised by a narrow therapeutic index or a rapidly varying analgesic requirement. Prolonged release opioids should not be used for acute post-operative pain owing to the increased risk of persistent post-operative opioid use (PPOU) and opioid-induced ventilatory impairment (OIVI).
Buprenorphine may lower the seizure threshold in patients with a history of seizure disorder.
Severe febrile illness may increase the rate of buprenorphine absorption from BuTrans transdermal patches.
Endocrine system
Opioids may influence the hypothalamic-pituitary-adrenal or –gonadal axes. Some changes that can be seen include an increase in serum prolactin, and decreases in plasma cortisol and testosterone. Clinical symptoms may be manifest from these hormonal changes.
BuTrans should not be used at higher doses than recommended.
Effect of other active substances on the pharmacokinetics of buprenorphine
Buprenorphine is primarily metabolised by glucuronidation and to a lesser extent (about 30%) by CYP3A4. Concomitant treatment with CYP3A4 inhibitors may lead to elevated plasma concentrations with intensified efficacy of buprenorphine.
Studies with the CYP3A4 inhibitor ketoconazole did not produce clinically relevant increases in mean maximum (Cmax) or total (AUC) buprenorphine exposure following BuTrans with ketoconazole as compared to BuTrans alone.
The interaction between buprenorphine and CYP3A4 enzyme inducers has not been studied. Co-administration of BuTrans and enzyme inducers (e.g. phenobarbital, carbamazepine, phenytoin and rifampicin) could lead to increased clearance which might result in reduced efficacy.
Reductions in hepatic blood flow induced by some general anaesthetics (e.g. halothane) and other medicinal products may result in a decreased rate of hepatic elimination of buprenorphine.
Pharmacodynamic interactions
BuTrans must not be used concomitantly with MAOIs or in patients who have received MAOIs within the previous two weeks (see section 4.3).
BuTrans should be used cautiously when co-administered with:
Serotonergic medicinal products, such as MAO inhibitors, selective serotonin re-uptake inhibitors (SSRIs), serotonin norepinephrine re-uptake inhibitors (SNRIs) or tricyclic antidepressants as the risk of serotonin syndrome, a potentially life-threatening condition, is increased (see section 4.4).
Other central nervous system depressants: other opioid derivatives (analgesics and antitussives containing e.g. morphine, dextropropoxyphene, codeine, dextromethorphan or noscapine). Certain antidepressants, sedative H1-receptor antagonists, alcohol, anxiolytics, neuroleptics, clonidine and related substances. These combinations increase the CNS depressant activity.
The concomitant use of BuTrans with gabapentinoids (gabapentin and pregabalin) may result in respiratory depression, hypotension, profound sedation, coma or death (see section 4.4).
Concomitant administration of buprenorphine with anticholinergics or medications with anticholinergic activity (e.g. tricyclic antidepressants, antihistamines, antipsychotics, muscle relaxants, anti-Parkinson drugs) may results in increased anticholinergic adverse effects.
Sedative medicines such as benzodiazepines or related drugs as concomitant use increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. The dose and duration of concomitant use should be limited (see section 4.4). Such agents include sedatives or hypnotics, general anaesthetics, other opioid analgesics, phenothiazines, centrally acting anti-emetics, benzodiazepines and alcohol.
At typical analgesic doses buprenorphine is described to function as a pure mu receptor agonist. In BuTrans clinical studies subjects receiving full mu agonist opioids (up to 90 mg oral morphine or oral morphine equivalents per day) were transferred to BuTrans. There were no reports of abstinence syndrome or opioid withdrawal during conversion from entry opioid to BuTrans (see section 4.4).
Pregnancy
There are no or limited amounts of data from the use of BuTrans in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.
Buprenorphine crosses the placenta and buprenorphine and the active metabolite norbuprenorphine can be detected in newborn serum, urine and meconium following in utero exposure.
Towards the end of pregnancy high doses of buprenorphine may induce respiratory depression in the neonate even after a short period of administration. Therefore, BuTrans should not be used during pregnancy and in women of childbearing potential who are not using effective contraception unless the potential benefit justifies the potential risk to the foetus.
Regular use during pregnancy may cause drug dependence in the foetus, leading to withdrawal symptoms in the neonate.
If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.
Administration during labour may depress respiration in the neonate and an antidote for the child should be readily available.
Breastfeeding
Administration to nursing women is not recommended as buprenorphine is secreted in breast milk and may cause respiratory depression in the infant. Studies in rats have shown that buprenorphine may inhibit lactation. Available pharmacodynamic/toxicological data in animals has shown excretion of buprenorphine in milk (see section 5.3). A risk to the newborn/infants cannot be excluded. BuTrans should be used with caution during breast-feeding.
Fertility
No human data on the effect of buprenorphine on fertility are available. In a fertility and early embryonic development study, no effects on reproductive parameters were observed in male or female rats (see section 5.3).
BuTrans has a major influence on the ability to drive and use machines. Even when used according to instructions, BuTrans may affect the patient's reactions to such an extent that road safety and the ability to operate machinery may be impaired. This applies particularly in the beginning of treatment and in conjunction with other centrally acting substances including alcohol, tranquillisers, sedatives and hypnotics. An individual recommendation should be given by the physician. A general restriction is not necessary in cases where a stable dose is used.
Patients who are affected and experience side effects (e.g. dizziness, drowsiness, blurred vision) during treatment initiation or titration to a higher dose should not drive or use machines for at least 24 hours after the patch has been removed.
This medicine can impair cognitive function and can affect a patient's ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:
• The medicine is likely to affect your ability to drive.
• Do not drive until you know how the medicine affects you.
• It is an offence to drive while you have this medicine in your body over a specified limit unless you have a defence (called the 'statutory defence').
• This defence applies when:
o
The medicine has been prescribed to treat a medical or dental problem; and
o
You have taken it according to the instructions given by the prescriber and in the information provided with the medicine.
• Please note that it is still an offence to drive if you are unfit because of the medicine (i.e. your ability to drive is being affected).”
Details regarding a new driving offence concerning driving after drugs have been taken in the UK may be found here: https://www.gov.uk/drug-driving-law
Serious adverse reactions that may be associated with BuTrans therapy in clinical use are similar to those observed with other opioid analgesics, including respiratory depression (especially when used with other CNS depressants) and hypotension (see section 4.4).
The following undesirable effects have occurred:
Very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1000, <1/100), rare (≥1/10,000, <1/1000), very rare (<1/10,000), not known (cannot be estimated from the available data).
System organ class
MedDRA
Very common
(≥1/10)
Common
(≥1/100, <1/10)
Uncommon
(≥1/1000, <1/100)
Rare
(≥1/10,000, <1/1000)
Very rare
(<1/10,000)
Not known (cannot be estimated from the available data)
Immune system disorders
Hypersensitivity
Anaphylactic reaction
Anaphylactoid reaction
Metabolic and nutritional disorders
Anorexia
Dehydration
Psychiatric disorders
Confusion
Depression
Insomnia
Nervousness
Anxiety
Affect lability
Sleep disorder
Restlessness
Agitation
Euphoric mood
Hallucinations
Decreased libido
Nightmares
Aggression
Psychotic disorder
Mood swings
Drug dependence (see section 4.4)
Depersonalisation
Nervous system disorders
Headache
Dizziness
Somnolence
Tremor
Sedation
Dysgeusia
Dysarthria
Hypoaesthesia
Memory impairment
Migraine
Syncope
Abnormal coordination
Disturbance in attention
Paraesthesia
Balance disorder
Speech disorder
Involuntary muscle contractions
Seizures,
Sleep apnoea syndrome,
Hyperalgesia
Eye disorders
Dry eye
Blurred vision
Visual disturbance
Eyelid oedema
Miosis
Ear and labyrinth disorders
Tinnitus
Vertigo
Ear pain
Cardiac disorders
Palpitations
Tachycardia
Angina pectoris
Vascular disorders
Hypotension
Circulatory collapse
Hypertension
Flushing
Vasodilatation
Orthostatic hypotension
Respiratory, thoracic and mediastinal disorders
Dyspnoea
Cough
Wheezing
Hiccups
Respiratory depression
Respiratory failure
Asthma aggravated
Hyperventilation
Rhinitis
Gastrointestinal disorders
Constipation
Nausea
Vomiting
Abdominal pain
Diarrhoea
Dyspepsia
Dry mouth
Flatulence
Dysphagia
Ileus
Diverticulitis
Hepatobiliary disorders
Biliary colic
Skin and subcutaneous tissue disorders
Pruritus
Erythema
Rash
Sweating
Exanthema
Dry skin
Urticaria
Face oedema
Pustules
Vesicles
Dermatitis contact,
Application skin discolouration
Musculoskeletal and connective tissue disorders
Muscular weakness
Myalgia
Muscle spasms
Renal and urinary disorders
Urinary incontinence
Urinary retention
Urinary hesitation
Reproductive system and breast disorders
Erectile dysfunction
Sexual dysfunction
General disorders and administration site conditions
Application site reactions1*
Tiredness
Asthenic conditions
Peripheral oedema
Fatigue
Pyrexia
Rigors
Oedema
Drug withdrawal syndrome
Chest pain
Influenza like illness
Drug withdrawal syndrome neonatal
Drug tolerance
Investigations
Alanine aminotransferase increased
Weight decreased
Injury, poisoning and procedural complications
Accidental injury
Fall
1 Includes common signs and symptoms of contact dermatitis (irritative or allergic): erythema, oedema, pruritus, rash, vesicles, painful/burning sensation at the application site.
*In some cases delayed local allergic reactions (allergic contact dermatitis) occurred with marked signs of inflammation. Mechanical injuries during patch removal (e.g. laceration) are also possible in patients with fragile skin. Chronic inflammation may lead to long-lasting sequelae, such as post inflammatory hyper- and hypopigmentation, as well as dry and thick scaly skin lesions, which may closely resemble scars. In such cases treatment with BuTrans should be terminated (see sections 4.3 and 4.4).
Drug dependence
Repeated use of BuTrans can lead to drug dependence, even at therapeutic doses. The risk of drug dependence may vary depending on a patient's individual risk factors, dosage, and duration of opioid treatment (see section 4.4).
After discontinuation of BuTrans, withdrawal symptoms are uncommon. This may be due to the very slow dissociation of buprenorphine from the opioid receptors and to the gradual decrease of buprenorphine plasma concentrations (usually over a period of 30 hours after removal of the last patch).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Symptoms
Symptoms similar to those of other centrally acting analgesics are to be expected. These may include respiratory depression, including apnoea, sedation, drowsiness, nausea, vomiting, cardiovascular collapse and marked miosis.
Patients should be informed of the signs and symptoms of overdose and to ensure that family and friends are also aware of these signs and to seek immediate medical help if they occur.
Treatment
Remove any patches from the patient's skin.
Establish and maintain a patent airway, assist or control respiration as indicated and maintain adequate body temperature and fluid balance. Oxygen, intravenous fluids, vasopressors and other supportive measures should be employed as indicated.
A specific opioid antagonist such as naloxone may reverse the effects of buprenorphine, although naloxone may be less effective in reversing the effects of buprenorphine than other µ-opioid agonists. Treatment with continuous intravenous naloxone should begin with the usual doses but high doses may be required.
Ask anything about BuTrans 5 microgram/hour transdermal patch. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.